{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T02:14:37Z","timestamp":1782267277774,"version":"3.54.5"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["F4701-B20"],"award-info":[{"award-number":["F4701-B20"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["F4704-B20"],"award-info":[{"award-number":["F4704-B20"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["P30625"],"award-info":[{"award-number":["P30625"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006546","name":"Angelini Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006546","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ebiom.2019.11.004","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T09:46:14Z","timestamp":1574329574000},"page":"111-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["CDK4\/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML"],"prefix":"10.1016","volume":"50","author":[{"given":"Mathias","family":"Schneeweiss-Gleixner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Byrgazov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Stefanzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Eisenwort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal Blanche","family":"Lucini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Herndlhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Preuner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klara","family":"Obrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Pusic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Witzeneder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Greiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Hoermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang R.","family":"Sperr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Deininger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline V.","family":"Gleixner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2019.11.004_bib0001","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2019.11.004_bib0002","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","article-title":"Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV","volume":"32","author":"Hehlmann","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2019.11.004_bib0003","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/leu.2015.152","article-title":"GIMEMA CML Working Party. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib","volume":"29","author":"Castagnetti","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.ebiom.2019.11.004_bib0004","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"issue":"S1","key":"10.1016\/j.ebiom.2019.11.004_bib0005","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1053\/j.seminhematol.2006.12.002","article-title":"Resistance to targeted therapy in chronic myelogenous leukemia","volume":"44","author":"Hochhaus","year":"2007","journal-title":"Semin Hematol"},{"key":"10.1016\/j.ebiom.2019.11.004_bib0006","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ddtec.2014.03.003","article-title":"Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia","volume":"11","author":"Balabanov","year":"2014","journal-title":"Drug Discov Today Technol"},{"issue":"5","key":"10.1016\/j.ebiom.2019.11.004_bib0007","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.clml.2013.03.018","article-title":"Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options","volume":"13","author":"Jabbour","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"27","key":"10.1016\/j.ebiom.2019.11.004_bib0008","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","article-title":"Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter","volume":"114","author":"Branford","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2019.11.004_bib0009","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"European Leukemianet. Chronic myeloid leukemia: an update of concepts and management recommendations of European Leukemianet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.ebiom.2019.11.004_bib0010","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1158\/1078-0432.CCR-08-0117","article-title":"Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia","volume":"14","author":"Quint\u00e1s-Cardama","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ebiom.2019.11.004_bib0011","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","article-title":"Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors","volume":"31","author":"Patel","year":"2017","journal-title":"Hematol Oncol Clin N Am"},{"issue":"5","key":"10.1016\/j.ebiom.2019.11.004_bib0012","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"issue":"19","key":"10.1016\/j.ebiom.2019.11.004_bib0013","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ebiom.2019.11.004_bib0014","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","article-title":"Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors","volume":"125","author":"Valent","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ebiom.2019.11.004_bib0015","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/leu.2013.320","article-title":"Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib","volume":"28","author":"Mayer","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.ebiom.2019.11.004_bib0016","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1016\/S2352-3026(15)00127-1","article-title":"Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study","volume":"2","author":"Jain","year":"2015","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.ebiom.2019.11.004_bib0017","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","article-title":"BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships","volume":"121","author":"Khorashad","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ebiom.2019.11.004_bib0018","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1073\/pnas.1321173111","article-title":"Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy","volume":"111","author":"Gibbons","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/j.ebiom.2019.11.004_bib0019","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.ebiom.2019.11.004_bib0020","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.3324\/haematol.2017.176347","article-title":"BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib","volume":"103","author":"Byrgazov","year":"2018","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.ebiom.2019.11.004_bib0021","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.bbmt.2016.03.012","article-title":"Allogeneic stem cell transplantation for patients with T315I BCR-ABL mutated chronic myeloid leukemia","volume":"22","author":"Xu","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"10.1016\/j.ebiom.2019.11.004_bib0022","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrclinonc.2015.193","article-title":"Allogeneic transplantation for CML in the TKI era: striking the right balance","volume":"13","author":"Innes","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"15","key":"10.1016\/j.ebiom.2019.11.004_bib0023","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1002\/cncr.30558","article-title":"Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation","volume":"123","author":"Nicolini","year":"2017","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ebiom.2019.11.004_bib0024","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40261-018-0623-7","article-title":"Low-dose ponatinib in intolerant chronic myeloid leukemia patients: a safe and effective option","volume":"38","author":"Iurlo","year":"2018","journal-title":"Clin Drug Investig"},{"issue":"4","key":"10.1016\/j.ebiom.2019.11.004_bib0025","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/hon.2517","article-title":"Upfront low-dose ponatinib (15 mg\/day) for multi-TKI resistant chronic myeloid leukemia","volume":"36","author":"Tefferi","year":"2018","journal-title":"Hematol Oncol"},{"issue":"1","key":"10.1016\/j.ebiom.2019.11.004_bib0026","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1111\/bjh.16132","article-title":"Efficacy and safety of low dose ponatinib in a case of Ph-positive acute lymphoblastic leukaemia","volume":"187","author":"Marchesi","year":"2019","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.ebiom.2019.11.004_bib0027","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/leu.2014.326","article-title":"PF-114, a potent and selective inhibitor of native and mutated BCR\/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation","volume":"29","author":"Mian","year":"2015","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"10.1016\/j.ebiom.2019.11.004_bib0028","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2018-99-116803","article-title":"Phase-1 study of PF-114 mesylate in CML failing prior tyrosine kinase-inhibitor therapy","volume":"132","author":"Turkina","year":"2018","journal-title":"Blood."},{"issue":"Suppl 1","key":"10.1016\/j.ebiom.2019.11.004_bib0029","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1182\/blood-2018-99-113609","article-title":"Asciminib, a specific allosteric BCR-ABL1 inhibitor, in patients with chronic myeloid leukemia carrying the T315I mutation in a phase 1 trial","volume":"132","author":"Rea","year":"2018","journal-title":"Blood."},{"issue":"3 Suppl 9","key":"10.1016\/j.ebiom.2019.11.004_bib0030","first-page":"21","article-title":"The evolution of hydroxyurea therapy in chronic myelogenous leukemia","volume":"19","author":"Kennedy","year":"1992","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1016\/j.ebiom.2019.11.004_bib0031","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1182\/blood.V82.2.398.398","article-title":"Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group","volume":"82","author":"Hehlmann","year":"1993","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ebiom.2019.11.004_bib0032","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/sj.leu.2403006","article-title":"Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea","volume":"17","author":"Hehlmann","year":"2003","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.ebiom.2019.11.004_bib0033","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00277-008-0650-1","article-title":"Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients","volume":"88","author":"Spanoudakis","year":"2009","journal-title":"Ann Hematol"},{"issue":"26","key":"10.1016\/j.ebiom.2019.11.004_bib0034","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1182\/blood-2014-08-435768","article-title":"Update on the use of hydroxyurea therapy in sickle cell disease","volume":"124","author":"Wong","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ebiom.2019.11.004_bib0035","first-page":"481","article-title":"Involvement of p38 kinase in hydroxyurea-induced differentiation of K562 cells","volume":"12","author":"Park","year":"2001","journal-title":"Cell Growth Differ"},{"issue":"6","key":"10.1016\/j.ebiom.2019.11.004_bib0036","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1080\/10428190290026358","article-title":"Gene expression profiling in chronic myeloid leukemia patients treated with hydroxyurea","volume":"43","author":"Bruchova","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.ebiom.2019.11.004_bib0037","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European Leukemianet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ebiom.2019.11.004_bib0038","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European Leukemianet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.ebiom.2019.11.004_bib0039","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/leu.2009.168","article-title":"Harmonization of molecular monitoring of CML therapy in Europe","volume":"23","author":"M\u00fcller","year":"2009","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.ebiom.2019.11.004_bib0040","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European Leukemianet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ebiom.2019.11.004_bib0041","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/leu.2008.97","article-title":"Quantitative monitoring of cell clones carrying point mutations in the BCR-ABL tyrosine kinase domain by ligation-dependent polymerase chain reaction (LD-PCR)","volume":"22","author":"Preuner","year":"2008","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.ebiom.2019.11.004_bib0042","doi-asserted-by":"crossref","first-page":"5085","DOI":"10.1074\/jbc.M109.039206","article-title":"BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia","volume":"285","author":"Yuan","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ebiom.2019.11.004_bib0043","first-page":"7149","article-title":"Activity of the BCR-ABL kinase inhibitor PD180970 against clinically relevant BCR-ABL isoforms that cause resistance to imatinib mesylate (Gleevec, STI571)","volume":"62","author":"La Rosee","year":"2002","journal-title":"Cancer Res"},{"issue":"47","key":"10.1016\/j.ebiom.2019.11.004_bib0044","doi-asserted-by":"crossref","first-page":"78083","DOI":"10.18632\/oncotarget.12943","article-title":"Transposon-mediated generation of BCR-ABL1-expressing transgenic cell lines for unbiased sensitivity testing of tyrosine kinase inhibitors","volume":"7","author":"Byrgazov","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.ebiom.2019.11.004_bib0045","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1158\/0008-5472.CAN-09-2181","article-title":"Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536","volume":"70","author":"Gleixner","year":"2010","journal-title":"Cancer Res"},{"issue":"40","key":"10.1016\/j.ebiom.2019.11.004_bib0046","doi-asserted-by":"crossref","first-page":"67709","DOI":"10.18632\/oncotarget.18810","article-title":"The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase\/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells","volume":"28","author":"Stefanzl","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ebiom.2019.11.004_bib0047","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"issue":"10","key":"10.1016\/j.ebiom.2019.11.004_bib0048","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1038\/sj.leu.2404772","article-title":"BCR-ABLT315I transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge","volume":"21","author":"Legros","year":"2007","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.ebiom.2019.11.004_bib0049","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1182\/blood-2007-06-094508","article-title":"Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation","volume":"110","author":"De Lavallade","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ebiom.2019.11.004_bib0050","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0145-2126(88)90110-5","article-title":"Evidence for a selective antileukemic effect of cytosine arabinoside in chronic granulocytic leukemia","volume":"12","author":"Sokal","year":"1988","journal-title":"Leuk Res"},{"issue":"7647","key":"10.1016\/j.ebiom.2019.11.004_bib0051","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2019.11.004_bib0052","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.brainres.2007.10.074","article-title":"Expression of survivin and p16(INK4a)\/Cdk6\/pRB proteins and induction of apoptosis in response to radiation and cisplatin in meningioma cells","volume":"1188","author":"Al-Khalaf","year":"2008","journal-title":"Brain Res"},{"issue":"7","key":"10.1016\/j.ebiom.2019.11.004_bib0053","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","article-title":"Treating cancer with selective CDK4\/CDK6 inhibitors","volume":"13","author":"O'Leary","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"15","key":"10.1016\/j.ebiom.2019.11.004_bib0054","doi-asserted-by":"crossref","first-page":"7661","DOI":"10.1158\/0008-5472.CAN-06-1098","article-title":"A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4\/6","volume":"66","author":"Baughn","year":"2006","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.ebiom.2019.11.004_bib0055","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3324\/haematol.2010.030999","article-title":"Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy","volume":"96","author":"Hanfstein","year":"2011","journal-title":"Haematologica"},{"issue":"16","key":"10.1016\/j.ebiom.2019.11.004_bib0056","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1128\/MCB.02202-05","article-title":"Kinase domain mutants of BCR-ABL exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib","volume":"26","author":"Griswold","year":"2006","journal-title":"Mol Cell Biol"},{"issue":"2","key":"10.1016\/j.ebiom.2019.11.004_bib0057","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0165-1110(75)90002-0","article-title":"Hydroxyurea","volume":"32","author":"Timson","year":"1975","journal-title":"Mutat Res"},{"issue":"11","key":"10.1016\/j.ebiom.2019.11.004_bib0058","doi-asserted-by":"crossref","DOI":"10.3390\/genes7110099","article-title":"The cell killing mechanisms of hydroxyurea","volume":"7","author":"Singh","year":"2016","journal-title":"Genes"},{"key":"10.1016\/j.ebiom.2019.11.004_bib0059","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fcell.2015.00016","article-title":"Targeting cell cycle regulators in hematologic malignancies","volume":"3","author":"Aleem","year":"2015","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"10.1016\/j.ebiom.2019.11.004_bib0060","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1182\/blood-2014-06-584417","article-title":"CDK6 as a key regulator of hematopoietic and leukemic stem cell activation","volume":"125","author":"Scheicher","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ebiom.2019.11.004_bib0061","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc2368","article-title":"Getting to the stem of chronic myeloid leukaemia","volume":"8","author":"Savona","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.ebiom.2019.11.004_bib0062","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1158\/1535-7163.MCT-14-1065","article-title":"Specific antileukemic activity of PD0332991, a CDK4\/6 inhibitor, against Philadelphia chromosome-positive lymphoid leukemia","volume":"15","author":"Nemoto","year":"2016","journal-title":"Mol Cancer Ther"}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396419307455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396419307455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:55:22Z","timestamp":1762455322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396419307455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":62,"alternative-id":["S2352396419307455"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2019.11.004","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CDK4\/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2019.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}